InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. InVivo Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

InVivo Therapeutics Holdings Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Short-Term Debt & Capital Lease Obligation Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.10

0.29

0.33

0.36

0.40

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.39	0.40	0.44	0.47	-

InVivo Therapeutics Holdings Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

InVivo Therapeutics Holdings Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

04I:Germany

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

Executives

Brice Foose	10 percent owner	236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak	director	C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison	director	ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli	director, officer: CEO and CMO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher	officer: Chief Financial Officer	C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield	director
Bob Rosenthal	director	20 NEWBURY ST, BOSTON MA 02116
Heather Hamel	officer: Chief Legal Officer and GC	ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino	officer: See Remarks	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty	officer: Chief Financial Officer	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz	officer: Interim CFO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl	officer: Chief Commercial Officer	ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne	officer: Chief Medical Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070